Combination therapy of anti-TNF agent and immunomodulators have supported the fact that the therapeutic effect would be amplified by different target mechanisms, and a recent study suggested that the effect of combination therapy is owing to reduced immunogenicity and elevated infliximab blood concentration.[24] Hence, we assumed that combination therapy has synergistic risks in TB as compared with monotherapy using each drug. The gene discussed is TNF; the disease is tuberculosis.